Tag: CBT > Cannabis Schedule III

Cannabis Business Insurance

US Lawmakers Introduce Bill to Assist Cannabis Businesses in Getting Insurance

The bipartisan legislation aims to shield insurance companies that serve the cannabis industry from federal prosecution and liability.

September 17, 2026

Cannabis Rescheduling

Where Are We on Cannabis Rescheduling? It’s Been Months Since the US Attorney General’s April 2026 Order

There’s been no transparency about the applications of those seeking DEA registration. The IRS/Treasury has provided no guidance about what to do regarding §280E on those federal tax returns – even though, in April, the feds promised it would be forthcoming.

September 11, 2026

Cannabis Rescheduling

Federal Court Denies Anti-Rescheduling Parties’ Motion to Stay Schedule III Cannabis Order

The U.S. Court of Appeals for the District of Columbia Circuit won’t halt the Trump administration’s order that reclassified medical cannabis.

September 10, 2026

Cannabis Rescheduling

Will Judge’s Rescheduling Decision Be Influenced by Lone Opposed Party Witness DEA Did Not Discredit?

Some legal experts believe a pharmacologist’s testimony on currently accepted medical use could be the most damning for the Schedule III proposal.

August 28, 2026

Cannabis Rescheduling

DEA’s Final Schedule III Case Leads CBT’s Top Stories in August

The Drug Enforcement Administration tried to discredit nearly all opposing witnesses who testified during the rescheduling hearing in its post-hearing brief.

August 27, 2026

Cannabis Rescheduling

DEA Judge Releases Transcripts for Cannabis Rescheduling Hearing

With the fully corrected transcripts now part of the public record, the judge who oversaw the hearing’s proceedings now must make a recommendation.

August 25, 2026

Cannabis Rescheduling

DEA Judge Orders 294 Corrections to 2,500-Page Cannabis Hearing Transcript

The DEA’s administrative law judge said the fully corrected transcript for the cannabis rescheduling hearing will be made public no later than Aug. 26.

August 21, 2026

Cannabis Rescheduling

US House Members Push Trump Administration for Guidance on Schedule III Federal Framework

A bipartisan quartet of lawmakers sent a letter to Trump and three cabinet members, asking for clarity on the federal policy for medical cannabis.

August 19, 2026

Cannabis Rescheduling

DEA Makes Final Schedule III Case, Tries to Discredit Nearly All Opposing Witnesses

The government’s final brief for the cannabis rescheduling hearing focuses on currently accepted medical use, a scientific and medical analysis, and the opposition’s ‘so-called experts.’

August 19, 2026

Cannabis Rescheduling

What to Expect From the DEA’s Cannabis Rescheduling Hearing Transcripts, Final Briefs

A law judge’s recommendation may not come down to whether anti-rescheduling parties proved a Schedule I listing, but whether they disproved the government’s Schedule III evidence.

August 5, 2026

Compliance

Glass House Brands Retains Former DEA Compliance Executive to Advise on Interstate Commerce, Export Opportunities

Matt Murphy had a distinguished 26-year career with the DEA as a special agent and regulatory subject-matter expert.

July 27, 2026

Cannabis Rescheduling

DOJ Head Sidesteps Questions on Schedule III Order, Adult-Use Cannabis

Todd Blanche, Trump’s nominee to be the U.S. attorney general, answered questions for the record about his stances on rescheduling, 280E and enforcement.

July 21, 2026